Ultragenyx Pharmaceutical
$142.739876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$142.73
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$2.51 (+1.79%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours
Why Robinhood?
You can buy or sell RARE and other stocks, options, and ETFs commission-free!
About RARE
Ultragenyx Pharmaceutical Inc. Common Stock, also called Ultragenyx Pharmaceutical, is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA. The listed name for RARE is Ultragenyx Pharmaceutical Inc. Common Stock.
CEO
Emil D. Kakkis
Employees
893
Headquarters
Novato, California
Founded
2010
Market Cap
9.78B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
506.60K
High Today
$144.00
Low Today
$137.53
Open Price
$140.00
Volume
260.99K
52 Week High
$179.65
52 Week Low
$31.99
Analyst Ratings
59%
of 17 ratings
Buy
59%
Hold
41%
Sell
0%
RARE Earnings
-$2.05
-$1.49
-$0.93
-$0.37
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$1.16 per share
Actual
-$0.37 per share